Endocrinology
- To repeat or not to repeat? Measuring bone mineral density during anti-resorptive therapy or a drug holiday
The authors present evidence for and against monitoring bone mineral density in these patients, arguing against a one-size-fits-all approach.
- The constellation of vitamin D, the acute-phase response, and inflammation
An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.
- Vitamin D: A metabolic bone disease perspective
When checking levels, clinicians should keep in mind that vitamin D levels fluctuate by season and time of day, and that different laboratories may use different assays that yield different results.
- Some complexities of diabetes and the heart
Patients with diabetes are at greater risk of coronary artery disease than their peers without diabetes. That’s straight and simple. But there the simplicity ends.
- Bone turnover markers to monitor oral bisphosphonate therapy
Rapid changes in levels of bone turnover markers can be useful in monitoring the effectiveness of therapy and improving adherence to therapy.
- Making best use of bone turnover markers to monitor oral bisphosphonate therapy
Clinical applications of bone turnover markers can include determining when to start or end a bisphosphonate “holiday” and measuring treatment response.
- Statins may increase diabetes, but benefit still outweighs risk
The weight of the evidence suggests that statin use is associated with an increased risk of new-onset diabetes mellitus, but the magnitude of the effect has varied across studies.
- Is your patient at risk for NAFLD?
The authors review identifying individuals at risk, treatment options founded on lifestyle modification, and when to consider referring patients to a hepatologist.
- Hypophosphatemia in a patient with an eating disorder
A 32-year-old woman referred from an eating disorder treatment center reported memory difficulty, trouble concentrating, and feeling “hazy.” She was taking oral potassium phosphate 3 times daily.
- The role of GLP-1 receptor agonists in managing type 2 diabetes
The following article in the August 2022 issue contained an error: Nachawi N, Rao PP, Makin V. The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleve Clin J Med 2022; 89(8): 457–464. doi:10.3949/ccjm.89a.21110